

HR 4597

ACCESS for Biosimilars Act of 2019

Congress: 116 (2019–2021, Ended)

Chamber: House

Policy Area: Health

Introduced: Oct 1, 2019

Current Status: Referred to the Subcommittee on Health.

Latest Action: Referred to the Subcommittee on Health. (Oct 2, 2019)

Official Text: <https://www.congress.gov/bill/116th-congress/house-bill/4597>

Sponsor

Name: Rep. Peters, Scott H. [D-CA-52]

Party: Democratic • **State:** CA • **Chamber:** House

Cosponsors (2 total)

Cosponsor	Party / State	Role	Date Joined
Rep. Brindisi, Anthony [D-NY-22]	D · NY		Oct 1, 2019
Rep. King, Peter T. [R-NY-2]	R · NY		Oct 1, 2019

Committee Activity

Committee	Chamber	Activity	Date
Energy and Commerce Committee	House	Referred to	Oct 2, 2019
Ways and Means Committee	House	Referred to	Oct 1, 2019

Subjects & Policy Tags

Policy Area:

Health

Related Bills

Bill	Relationship	Last Action
116 S 3466	Related bill	Mar 12, 2020: Read twice and referred to the Committee on Finance.

Summary (as of Oct 1, 2019)

Acting to Cancel Copays and Ensure Substantial Savings for Biosimilars Act of 2019 or the ACCESS for Biosimilars Act of 2019

This bill eliminates cost-sharing for biosimilar biological products for certain qualifying beneficiaries under Medicare medical services. Specifically, the bill eliminates cost-sharing for beneficiaries whose coverage under private health insurance, a federal program (other than Medicare), a Medicare supplemental policy, or Medicare Advantage does not already do so. The Centers for Medicare & Medicaid Services must establish a process for determining a beneficiary's eligibility and notifying Medicare Advantage organizations of such determinations.

Actions Timeline

- **Oct 2, 2019:** Referred to the Subcommittee on Health.
- **Oct 1, 2019:** Introduced in House
- **Oct 1, 2019:** Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
- **Oct 1, 2019:** Referred to the Subcommittee on Health.